Search results
Results From The WOW.Com Content Network
Prostate cancer is a major topic of ongoing research. From 2016–2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [121] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost. [122]
Detect prostate cancer (when no symptoms are present) Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [ 1][ 2] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates ...
A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 ( 68 ...
A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, [1] epigenetic, [2] proteomic, [3] glycomic, [4] and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood ...
Prostate-specific antigen (PSA, also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen) is a 34- kD glycoprotein produced almost exclusively by the prostate gland. It is a serine protease ( EC 3.4.21.77) enzyme, the gene of which is located on the 19th chromosome (19q13) in humans. [ 28]
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy ( prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship ...
Early prostate cancer antigen-2. Early prostate cancer antigen-2 ( EPCA-2) is a protein of which blood levels are elevated in prostate cancer. It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA . "EPCA-2" is not the name of a gene. EPCA-2 gets its name because it is the second ...
PCA3. Prostate cancer antigen 3 ( PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer. [3] [4] Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker. [5]